Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort

Journal of Autoimmunity

Volumn 84, Issue , 2017, Pages 55-64

  Tansley, Sarah L ^a,b   Simou, Stefania ^c   Shaddick, Gavin ^d   Betteridge, Zoe E ^b   Almeida, Beverley ^c,e   Gunawardena, Harsha ^f   Thomson, Wendy ^g   Beresford, Michael W ^h,i,j   Midgley, Angela ^h,j   Muntoni, Francesco ^c   Wedderburn, Lucy R ^c,e,k   McHugh, Neil J ^a,b  

^a ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES   (United Kingdom)

^b University of Bath   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d University of Bath   (United Kingdom)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^f SOUTHMEAD HOSPITAL   (United Kingdom)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h UNIVERSITY OF LIVERPOOL   (United Kingdom)

ⁱ ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^j Arthritis Research UK Experimental Arthritis Treatment Centre for Children   (United Kingdom)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Autoantibody; Autoimmune disease; Myopathy; Myositis; Paediatric rheumatology; Phenotype

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A REDUCTASE ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; CYCLOPHOSPHAMIDE; MELANOMA DIFFERENTIATION ASSOCIATED PROTEIN 5 ANTIBODY; MI2 ANTIBODY; NUCLEAR MATRIX PROTEIN 2 ANTIBODY; P155 140 ANTIBODY; RIBONUCLEOPROTEIN ANTIBODY; SIGNAL RECOGNITION PEPTIDE ANTIBODY; SMALL UBIQUITIN LIKE MODIFIER ACTIVATING ENZYME ANTIBODY; TIF1 GAMMA AUTOANTIBODY; TRNA SYNTHETASE ANTIBODY; U1 RIBONUCLEOPROTEIN ANTIBODY; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT; TRANSCRIPTION FACTOR; TRIM33 PROTEIN, HUMAN;

ADULT; ARTICLE; CALCINOSIS; CHILD; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; MYOSITIS; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RISK REDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCER; UNITED KINGDOM; ADOLESCENT; BLOOD; DERMATOMYOSITIS; IMMUNOLOGY; PREDICTIVE VALUE; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; AUTOANTIBODIES; BIOMARKERS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYCLOPHOSPHAMIDE; DERMATOMYOSITIS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 85021144635     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2017.06.007     Document Type: Article

References (37)

1. Martin, N., Krol, P., Smith, S., Murray, K., Pilkington, C.A., Davidson, J.E., et al. A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies. Rheumatology 50:1 (2011), 137–145.
2. Tansley, S.L., Betteridge, Z.E., Shaddick, G., Gunawardena, H., Arnold, K., Wedderburn, L.R., et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology 53:12 (2014), 2204–2208.
3. Tansley, S.L., Betteridge, Z.E., Gunawardena, H., Jacques, T.S., Owens, C.M., Pilkington, C., et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res. Ther., 16(4), 2014, R138.
4. Rider, L.G., Shah, M., Mamyrova, G., Huber, A.M., Rice, M.M., Targoff, I.N., et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine 92:4 (2013), 223–243.
5. Gunawardena, H., Wedderburn, L.R., North, J., Betteridge, Z., Dunphy, J., Chinoy, H., et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology 47:3 (2008), 324–328.
6. Gunawardena, H., Betteridge, Z.E., McHugh, N.J., Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology 48:6 (2009), 607–612.
7. Bingham, A., Mamyrova, G., Rother, K.I., Oral, E., Cochran, E., Premkumar, A., et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine 87:2 (2008), 70–86.
8. Deakin, C.T., Yasin, S.A., Simou, S., Arnold, K.A., Tansley, S.L., Betteridge, Z.E., et al. Muscle biopsy in combination with myositis-specific autoantibodies aids prediction of outcomes in juvenile dermatomyositis. Arthritis Rheumatol. 68:11 (2016), 2806–2816.
9. Huber, A.M., Mamyrova, G., Lachenbruch, P.A., Lee, J.A., Katz, J.D., Targoff, I.N., et al. Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies. Arthritis Care Res. 66:5 (2014), 732–740.
10. Bowyer, S.L., Blane, C.E., Sullivan, D.B., Cassidy, J.T., Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J. Pediatr. 103:6 (1983), 882–888.
11. Ramanan, A.V., Campbell-Webster, N., Ota, S., Parker, S., Tran, D., Tyrrell, P.N., et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheumatol. 52:11 (2005), 3570–3578.
12. Fisler, R.E., Liang, M.G., Fuhlbrigge, R.C., Yalcindag, A., Sundel, R.P., Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J. Am. Acad. Dermatol. 47:4 (2002), 505–511.
13. Mammen, A.L., Casciola-Rosen, L., Christopher-Stine, L., Lloyd, T.E., Wagner, K.R., Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease. Neurol. Neuroimmunol. Neuroinflamm., 2(6), 2015, e172.
14. Bohan, A., Peter, J.B., Polymyositis and dermatomyositis (first of two parts). N. Eng. J. M. 292:7 (1975), 344–347.
15. Lovell, D.J., Lindsley, C.B., Rennebohm, R.M., Ballinger, S.H., Bowyer, S.L., Giannini, E.H., et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheumatol. 42:10 (1999), 2213–2219.
16. Ruperto, N., Pistorio, A., Oliveira, S., Zulian, F., Cuttica, R., Ravelli, A., et al. Prednisone versus prednisone plus cyclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet 387:10019 (2016), 671–678.
17. Adib, N., Hyrich, K., Thornton, J., Lunt, M., Davidson, J., Gardner-Medwin, J., et al. Association between duration of symptoms and severity of disease at first presentation to paediatric rheumatology: results from the Childhood Arthritis Prospective Study. Rheumatology 47:7 (2008), 991–995.
18. Watson, L., Leone, V., Pilkington, C., Tullus, K., Rangaraj, S., McDonagh, J.E., et al. Disease activity, severity, and damage in the UK juvenile-onset systemic lupus erythematosus cohort. Arthritis Rheumatol. 64:7 (2012), 2356–2365.
19. Gunawardena, H., Wedderburn, L.R., Chinoy, H., Betteridge, Z.E., North, J., Ollier, W.E., et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheumatol. 60:6 (2009), 1807–1814.
20. McHugh, N., James, I., Maddison, P., Clinical significance of antibodies to a 68 kDa U1RNP polypeptide in connective tissue disease. J. Rheumatol. 17:10 (1990), 1320–1328.
21. Klein, M., Mann, H., Plestilova, L., Zamecnik, J., Betteridge, Z., McHugh, N., et al. Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience. Rheumatology 54:11 (2015), 2010–2014.
22. Team, R.C., R: a Language and Environment for Statistical Computing. 2012, R Foundation for Statistical Computing Vienna, Austria http://www.R-project.org/.
23. Calcagno, V., de Mazancourt, C., Glmulti: an R package for easy automated model selection with (generalized) linear models. J. Stat. Softw., 34(i12), 2010.
24. Huber, A.M., Feldman, B.M., Rennebohm, R.M., Hicks, J.E., Lindsley, C.B., Perez, M.D., et al. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheumatol. 50:5 (2004), 1595–1603.
25. Betteridge, Z.E., Gunawardena, H., Chinoy, H., North, J., Ollier, W.E., Cooper, R.G., et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann. Rheum. Dis. 68:10 (2009), 1621–1625.
26. Ambrose, N., Morgan, T.A., Galloway, J., Ionnoau, Y., Beresford, M.W., Isenberg, D.A., Differences in disease phenotype and severity in SLE across age groups. Lupus 25:14 (2016), 1542–1550.
27. Wedderburn, L.R., McHugh, N.J., Chinoy, H., Cooper, R.G., Salway, F., Ollier, W.E., et al. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology 46:12 (2007), 1786–1791.
28. Tansley, S., Wedderburn, L.R., Comparing and contrasting clinical and serological features of juvenile and adult-onset myositis: implications for pathogenesis and outcomes. Curr. Opin. Rheumatol. 27:6 (2015), 601–607.
29. Tansley, S.L., Betteridge, Z.E., Simou, S., Jacques, T.S., Pilkington, C., Wood, M., et al. Anti-HMGCR autoantibodies in juvenile idiopathic inflammatory myopathies identify a rare but clinically important subset of patients. J. Rheumatol., 2017, 10.3899/jrheum.160871 Epub ahead of print.
30. Pinal-Fernandez, I., Parks, C., Werner, J.L., Albayda, J., Paik, J., Danoff, S., et al. Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle. Arthritis Care Res. 69:2 (2017), 263–270.
31. Vermaak, E., Tansley, S., McHugh, N., The evidence for immunotherapy in dermatomyositis and polymyositis: a systematic review. Clin. Rheumatol. 34:12 (2015 Dec), 2089–2095.
32. Gordon, P.A., Winer, J.B., Hoogendijk, J.E., Choy, E.H., Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst. Rev., 8, 2012, CD003643.
33. Barsotti, S., Terenzi, R., La Paglia, G.M., Bellucci, E., Baldini, C., Neri, R., One year in review 2015: idiopathic inflammatory myopathies. Clin. Exp. Rheumatol. 33:5 (2015), 593–601.
34. Reed, A.M., Crowson, C.S., Hein, M., de Padilla, C.L., Olazagasti, J.M., Aggarwal, R., et al. Biologic predictors of clinical improvement in rituximab-treated refractory myositis. BMC Musculoskeletdisord., 16(1), 2015, 257.
35. Aggarwal, R., Bandos, A., Reed, A.M., Ascherman, D.P., Barohn, R.J., Feldman, B.M., et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile Dermatomyositis and adult polymyositis. Arthritis Rheumatol. 66:3 (2014), 740–749.
36. Bundell, C., Rojana-Udomsart, A., Mastaglia, F., Hollingsworth, P., McLean-Tooke, A., Diagnostic performance of a commercial immunoblot assay for myositis antibody testing. Pathology 48:4 (2016), 363–366.
37. Cavazzana, I., Fredi, M., Ceribelli, A., Mordenti, C., Ferrari, F., Carabellese, N., et al. Testing for myositis specific autoantibodies: comparison between line blot and immunoprecipitation assays in 57 myositis sera. J. Immunol. Methods 433 (2016), 1–5.